Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
OneSource Specialty Pharma is a specialty pharmaceutical CDMO demerged from Strides Pharma Science and listed in 2025, focused on drug-device combinations (injectable pens and cartridges, including GLP-1 related fill-finish capacity), biologics drug substance/product, sterile injectables and soft gelatin capsules. It provides contract development and manufacturing to global pharma and biotech clients from Indian facilities. Its positioning around GLP-1 device-filling capacity has been the central investor thesis.
Onesource Specialty Pharma Ltd. is a constituent of NIFTY 500, NIFTY SMALLCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Onesource Specialty Pharma Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 |
|---|---|---|
| EPS (basic, ₹) | -6.44 | -1.63 |
| Book value / share (₹) | 508.75 | 513.90 |
| Return on equity | -1.3% | -0.3% |
| Return on capital employed | 0.4% | 3.0% |
| Operating margin | 1.8% | 13.3% |
| Net margin | -5.2% | -1.2% |
| EBITDA | ₹304 Cr | ₹467 Cr |
| Free cash flow | ₹-561 Cr | ₹-22 Cr |
| Total debt | ₹1,276 Cr | ₹772 Cr |
| Debt to equity | 0.22 | 0.13 |
| Interest coverage | 0.2 | 1.2 |
| Current ratio | 0.99 | 0.98 |
| Shares outstanding | 11,46,20,000 | 11,44,30,000 |
Open the full income statement, balance sheet and cash flow for ONESOURCE →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.